Ergocalciferol/phytomenadione/retinol/tocopherol (vitamins A/D/E/K)
Generic name
Ergocalciferol/phytomenadione/retinol/tocopherol (vitamins A/D/E/K)
Brand name
ATC Code
B05XC
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Supplementation of lipid-soluble vitamins |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects
No information is present at this moment.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Per kg bodyweight, the need for vitamins is much greater in neonates than in adults. The vitamin status of the mother is not the same as the vitamin status of the neonate at birth. Transportation of fat-soluble vitamins through the placental membrane is limited. The concentrations of these vitamins are lower in neonates than in the mother. In neonates and in particular in premature infants, the lower reserves of fat-soluble vitamins should be taken into account. In the older children, there are considerable reserves of fat-soluble vitamins stocked in the body.
Young children and premature infants are more sensitive to vitamin D, resulting more quickly in overdoses with symptoms of hypercalcaemia and osteopenia.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| BLOOD AND RELATED PRODUCTS | ||
|---|---|---|
| B05AA01 | ||
| B05AA06 | ||
| I.V. SOLUTIONS | ||
|---|---|---|
| B05BB01 | ||
| B05BC01 | ||
| B05BB01 | ||
| B05BB03 | ||
| IRRIGATING SOLUTIONS | ||
|---|---|---|
| B05CX03 | ||
| B05CB10 | ||
| B05CB01 | ||
| I.V. SOLUTION ADDITIVES | ||
|---|---|---|
| B05XA07 | ||
| B05XA19 | ||
| B05XA14 | ||
| B05XB01 | ||
| B05XA31 | ||
| B05XA06 | ||
| HEMODIALYTICS AND HEMOFILTRATES | ||
|---|---|---|
| B05ZB | ||
References
- Rademaker C.M.A. et al, Geneesmiddelen-Formularium voor Kinderen, 2007
- Fresenius Kabi Nederland BV, SmPC Vitintra (RVG 16387) 17-09-2018, www.geneesmiddeleninformatiebank.nl
- Baxter Deutschland GmHb, SmPC Vitalipid Infant (24227.00.00), 10/2015
Changes
Therapeutic Drug Monitoring
Overdose
